Rivaroxaban Virtual Media Kit

The past decade has witnessed a growth of research into oral, direct Factor Xa inhibitors, and several are now in clinical development. Rivaroxaban is an investigational, oral, direct Factor Xa inhibitor being developed jointly by Johnson & Johnson Pharmaceutical Research & Development, LLC (J&J PRD) and Bayer HealthCare AG. Rivaroxaban is currently being evaluated by the U.S. Food & Drug Administration (U.S. FDA) for the prevention and treatment of a broad range of disorders in which blood clotting plays a major role.

The extensive program of clinical trials evaluating rivaroxaban makes rivaroxaban the most studied oral, direct Factor Xa inhibitor in the world today. More than 65,000 patients are expected to enroll in the rivaroxaban clinical development Phase 3 program, which includes the following trials:

  • RECORD: VTE prevention in patients undergoing total hip and total knee replacement
  • EINSTEIN: VTE treatment and secondary prevention
  • ROCKET AF: Stroke prevention in patients with atrial fibrillation
  • MAGELLAN: VTE prevention in medical, (non-surgical) patients
  • ATLAS ACS TIMI 51: Secondary prevention of acute coronary syndrome

Press Releases

About Rivaroxaban

About Arterial Blood Clots

About Venous Blood Clots

Image Library

  • Clot in the Heart: When the heart's rhythm is disrupted by atrial fibrillation, a clot can form in the left atrium and travel to the brain, causing an embolic stroke.
  • Heart/Head Path: A clot formed as a result of fibrillation can leave the heart and follow a direct path to the brain's arteries, causing an embolic stroke.
  • An Embolic Stroke: A blood clot formed in the heart can travel to the brain and lodge in one of the brain's arteries, causing an embolic stroke.